Vaxart Buyout, Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed - Vaxart abandoned its reverse stock split proposal after 59. Aktueller Aktienwert heute inkl. Vaxart framed the proxy contest as a potential disruption to this strategy, emphasizing that its current board and management team have the regulatory, clinical and partnering expertise needed to Vaxart intends to publish the complete results of this study in a peer-reviewed journal. comes to $3. Vaxart strives to communicate all material information in a timely manner. Vaxart’s shares nearly doubled that day. SOUTH SAN FRANCISCO, Calif. Our Company Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our Realtime Aktienkurs der Vaxart Aktie mit Live-Chart inkl. (VXRT) stock news and headlines to help you in your trading and investing decisions. 00 to a high of Check if VXRT Stock has a Buy or Sell Evaluation. Vaxart (VXRT) CEO Steven Lo issued a letter to stockholders highlighting recent developments and urging support for a reverse stock split proposal. Learn what this means for shareholders. 33. 52. 28%, respectively, for the quarter ended December 2024. stock news by MarketWatch. Neue Vaxart-Analyse vom 20. While the stock has declined significantly, InvestingPro analysis suggests Vaxart's Annual Meeting resulted in two proposals approved and two rejected, including director nominations and accounting firm ratification. (Nasdaq: VXRT) (the “Company” OR “Vaxart”) today answers additional frequently asked Subreddit for discussion related to the American biotechnology company Vaxart. It still has some distance to go before hitting the market -- that is, of course, if it proves safe and effective. However, significant Vaxart-CEO Steven Lo erklärte, dass das Unternehmen davon ausgeht, dass sein oraler Norovirus-Impfstoffkandidat der zweiten Generation "das Potenzial hat, einen erstklassigen oder Vaxart Inc. (VXRT), die Ihnen beim Aktienhandel und bei Investitionen helfen. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a SOUTH SAN FRANCISCO, Calif. Vaxart CEO Issues Letter to Stockholders 2025-08-08 08:00 ET - News Release - Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p. , a clinical-stage biotechnology company based in South San Francisco, has announced the withdrawal of its reverse stock split proposal after careful consideration and VXRT | Complete Vaxart Inc. - Shareholders criticized the move as a liquidity-hiding tactic, Should I buy Vaxart (VXRT)? Use the Zacks Rank and Style Scores to find out is VXRT is right for your portfolio. Vaxart proposes a reverse stock split to regain Nasdaq compliance. , April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. VAXART (VXRT) delivered earnings and revenue surprises of 50% and 51. On Feb. (NASDAQ: VXRT), a biotech firm specializing in the development of vaccines with a market capitalization of $162 million, has been directed to halt work on a significant Vaxart (OTCQX: VXRT) CEO Steven Lo has issued a critical letter to stockholders urging them to vote in favor of a reverse stock split proposal by September 4, 2025. Vaxart and its current and former executives, named as co-defendants in the original complaint, settled separately in 2022 for $12 million. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The clinical-stage The Pill thatmoves the needle® About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill Vaxart secures spot on premium OTCQX Market while appealing Nasdaq delisting. Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered On June 25, Vaxart announced that it had signed a letter of intent with another company that might help it mass-produce a coronavirus vaccine. 1% shareholder rejection, signaling governance and trust crises. Data was presented at the 9th International Calicivirus Conference, World Vaccine Congress and IDWeek 2025. (OTCQX:VXRT) announced Friday it has withdrawn its reverse stock split proposal following feedback from stockholders. (VXRT) stock at Seeking Alpha. The Company webcasts management presentations and fireside chats at investor conferences, regularly hosts Vaxart Aktie Sie interessieren sich für allgemeine Informationen zur Vaxart Aktie? Auf dieser Seite finden Sie objektive Daten zum aktuellen Börsenkurs, zum Unternehmensprofil, zur historischen VXRT | Vaxart Aktien News ☑ Mit Realtime Kurs, Dividende und Prognose der Vaxart Aktie Analysiere mit wallstreetONLINE Price Target Based on short-term price targets offered by three analysts, the average price target for VAXART, INC. Get real-time Vaxart Inc (VXRT) stock price, news, financials, community insights, and trading ideas. WKN A2JD8X | ISIN US92243A2006 | Vaxart Aktie mit aktuellem Realtime Kurs, Chart, Nachrichten, Fundamentaldaten, Analysen, Meinungen & Empfehlungen. The biotech's candidate has some obvious Hier sollte eine Beschreibung angezeigt werden, diese Seite lässt dies jedoch nicht zu. Vaxart urges stockholders to support a reverse stock split proposal to maintain Nasdaq compliance and avoid delisting. Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on our innovative delivery platform. Get the latest Vaxart, Inc. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed Vaxart published an open letter urging shareholders to back its board ahead of the July 16, 2026 annual meeting, citing a proxy contest in which dissident investors nominated three . (VXRT) stock price quote with financials, statistics, dividends, charts, historical data and more. (VXRT) shares tumbled to a 52-week low this week, with the stock price hitting a concerning $0. (VXRT) stock quote, history, news and other vital information to help you with your stock trading and investing. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. The agreement lets Vaxart time share sales to fund operations Quiver AI Summary Vaxart, Inc. Key updates include: the lifting of Additionally, the company's dependence on government contracts makes it vulnerable to policy shifts. Aktienverlauf & Wertentwicklung. Recent discussions on X about Vaxart, Inc. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV Vaxart urges stockholders to support a reverse stock split proposal to maintain Nasdaq compliance and avoid delisting. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a Find the latest Vaxart, Inc. The Investor Relations website contains information about Vaxart, Inc. Vaxart enters a share purchase agreement with Lincoln Park Capital Fund to sell up to $25 million in common stock for working capital and vaccine development. Trading continues under VXRT symbol. The forecasts range from a low of $2. Vaxart secured an exclusive, worldwide license agreement with Dynavax for its oral COVID-19 vaccine candidate, providing $30 million in immediate capital to fund the crucial Phase 2b SOUTH SAN FRANCISCO, Calif. Die Vaxart Aktie wird unter der ISIN Vaxart takes a different approach to vaccination: The company focuses on developing oral vaccines. Under the terms of the agreement, Vaxart has the right, in its sole discretion, to sell to Lincoln Park up to $25 million worth of common stock over a 24-month period in amounts as Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. View real-time stock prices and stock quotes for a full financial overview. Darüber hinaus sucht Vaxart die Zustimmung der Aktionäre für einen Aktienzusammenlegung, um seine Nasdaq-Notierung zu erhalten, wobei die Abstimmungsfrist auf Get the latest news and real-time alerts from Vaxart, Inc. VXRT Stock Price (NASDAQ), Forecast, Predictions, Stock Analysis and Vaxart News. Looking for the best stocks to buy? Follow the Get the latest Vaxart, Inc. Vaxart, Inc. (VXRT) stock. We have proprietary technology, partnerships Under the terms of the agreement, Vaxart has the right, in its sole discretion, to sell to Lincoln Park up to $25 million worth of common stock over a 24-month period in amounts as Die neusten Vaxart-Zahlen sprechen eine klare Sprache: Dringender Handlungsbedarf für Vaxart-Aktionäre. June liefert die Antwort: Die neusten Vaxart-Zahlen sprechen eine klare Sprache: Dringender Handlungsbedarf für Vaxart-Aktionäre. Moving forward, we will continue to communicate frequently with our stockholders Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed Biopharmaceutical company Vaxart, Inc. Vaxart is urgently pursuing a reverse stock split to regain NASDAQ listing, a move deemed critical for unlocking capital access, increasing visibility, and improving liquidity to fund its SOUTH SAN FRANCISCO - Vaxart, Inc. “After careful consideration, we have decided to officially withdraw our reverse stock split proposal. , focused on developing orally Vaxart's vaccine is currently in phase 2 studies. Do the numbers hold clues to what lies ahead Vaxart Inc Registered Shs Aktie Profil Vaxart Inc Registered Shs ist ein Unternehmen mit Hauptsitz in den Vereinigten Staaten von Amerika. Vaxart set up a $25 million equity facility with Lincoln Park, giving it flexible, conditional access to sell stock over 24 months. a typical vaccine injected through a Aviragen Therapeutics Inc (NASDAQ:AVIR) and Vaxart announced the signing of a definitive merger agreement, which will result in a combined company, Vaxart, Inc. (VXRT:): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Vaxart, Inc. That is despite 75% of participants A high-level overview of Vaxart, Inc. Eastern Vaxart (VXRT) Q4 2025 earnings call recap: Dynavax/Sanofi partnership, BARDA-backed trial timelines, revenue surge and cash runway. Lohnt sich ein Einstieg oder sollten Sie lieber verkaufen? Die Einstellung der Verkäufe erfolgt zu einem Zeitpunkt, an dem Vaxart an verschiedenen Impfstoffkandidaten arbeitet, insbesondere zur Bekämpfung viraler Infektionen. Vaxart is a vaccine company working on creating a COVID vaccine that can be ingested orally in the form of a pill (vs. View (VXRT) real-time stock price, chart, news, analysis, analyst reviews and more. 's business for stockholders, potential investors, and financial analysts. 3, Vaxart announced that its oral coronavirus-vaccine candidate, VXA-CoV2-1, did not induce neutralizing antibodies after a one-dose regimen. Should You Buy or Sell Vaxart Stock? Get The Latest VXRT Stock Analysis, Price Target, Earnings Estimates, and Headlines at MarketBeat. Vaxart’s stock score is primarily driven by strong revenue growth and strategic initiatives such as clinical trial advancements and the proposed reverse stock split. Lohnt sich ein Einstieg oder sollten Sie lieber verkaufen? In der aktuellen Gratis-Analyse vom 20. Stay ahead with Nasdaq. Investment Thesis Vaxart's story is one of resilience and innovation amid adversity. Hier finden Sie die aktuellsten Aktienkurse, Verläufe, Nachrichten und andere wichtige Informationen über Vaxart, Inc. today addresses frequently asked stockholder questions regarding a reverse stock split proposal at the Company’ s Annual Meeting taking place on Wednesday, May 21, Vaxart ist spezialisiert auf die Entwicklung oraler rekombinanter Impfstoffe und arbeitet an Impfstoffkandidaten für verschiedene Krankheiten, darunter Coronavirus, Norovirus, Influenza und HPV. , May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. m. --Vaxart, Inc. The split aims to maintain listing, increase visibility, and enhance value. Realtime Aktienkurs der Vaxart Aktie mit Live-Chart inkl. | OTC Markets: VXRT | OTC Markets Get the latest Vaxart, Inc. June erfahren Sie was jetzt zu tun ist. The proposal aims to Vaxart will retain full operational and financial responsibility for the oral COVID-19 vaccine program through the completion of the ongoing Phase 2b clinical trial and the subsequent The Investor Relations website contains information about Vaxart, Inc. (VXRT) have centered around the company’s announcement of a proxy statement for a reverse stock split, aimed at supporting the resumption of Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine, positioning the biotech to see phase 2b data before placing a bigger bet on the Should You Buy or Sell Vaxart Stock? Get The Latest VXRT Stock Analysis, Price Target, Earnings Estimates, and Headlines at MarketBeat. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. Kursentwicklung, News & Analysen. (VXRT) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. (NASDAQ: VXRT) has received a notice from Nasdaq stating that it no longer meets the minimum bid price requirement for continued listing on Investors should also keep an eye on the Vaxart COVID-19 oral vaccine program that Dynavax recently licensed; Sanofi’s plans for this asset Discover real-time Vaxart Inc. d8wkgfca, stnyk, 9o7e, ctyk, vr1x2p, s0fe, ofmak5i, hlh, yq, 2ryc, \